OMEC.AI is the first startup to emerge from the alliance of pharma companies and investors that created AION Labs, and will focus on improving the efficacy and safety of drug candidates.
The Danish company becomes the latest large pharma company to invest in NLRP3 assets, with these types of treatments holding the potential to treat a variety of diseases linked to inflammation.
The two companies have agreed an exclusive collaboration that will see Aptar’s SmartTrack testing service be complemented by Fluidda’s functional respiratory imaging technology.
TransCelerate BioPharma continues to work towards “bringing new medicines to patients faster”. We caught up with the organization’s CEO to hear about its main achievements over the past decade and learn about what comes next.
Meru Health has tasked decentralized clinical trial (DCT) specialist Curebase with supporting a study of its app-based treatment program for depression, burnout, and anxiety.
Outsourcing-Pharma caught up with Esther Mahillo, VP of Operational Strategy and Feasibility, Precision for Medicine to talk about advancements in patient enrollment in oncology and rare disease clinical trials.
Compliance data generated from the documentation of interactions with HCPs can be leveraged using AI and ML to the benefit of stakeholders across the industry, according to IQVIA.
Epic’s Life Sciences program is released with the aim to connect providers, pharmaceutical companies, and medical device manufacturers to recruit research participants, expand clinical trial access, and to speed up therapy development.
Parexel is utilizing a real-world evidence (RWE) strategy to understand patient populations, shorten timelines, and get treatments into patient’s hands.
Thermo Fisher Scientific’s clinical service unit PPD has won some “very large” customers since becoming part of the broader group in a mega-merger, according to CEO Marc Casper.
Science 37 has partnered with NuvoAir to incorporate connected devices for the remote collection of respiratory endpoints data into clinical trial designs.
GSK has struck a four-year contract to make Medable its preferred partner for decentralized clinical trials (DCTs), positioning the companies to work together to improve access to research.
Autoimmune diagnostics life sciences company Exagen is heralding the completion of the CAPSTONE study as evidence that its AVISE Lupus test is more clinically effective than traditional ANA methods (tANA), benefiting patients, providers and payers by...
The trial for Renovia’s leva Pelvic Health System used ObvioHealth’s platform to deliver real-time data while their virtual site team engaged with the patients via the app, resulting in a 94.5% compliance rate.
The virtual contract research organization (VCRO) Curavit Clinical Research has entered a long-term partnership with ixlayer. The partnership ushers in convenience for patients in Curavit’s trials.
Ensysce Biosciences has partnered with Quotient Sciences to develop an opioid to prevent abuse and overdose, enabling it to make mid-study changes to the formulation based on emerging data.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
The Digital Medicine Society is offering a library of resources to help promote the use of nocturnal scratch as an endpoint for the troubling skin condition.
The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company
The companies will work together to help clients connect information sources, giving stakeholders a better overview of the clinical patient experience.
With the purchase, the company is looking to advance its plans to connect with potential trial participants and spread awareness of study participation.
The Decentralized Trials and Research Alliance is offering the research resource to increase awareness, understanding, and acceptance of the study format.
A representative from the biometric contract research organization explains how taking a ‘patient comes first’ attitude can lead to a range of improvements.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
A leader suggests considering patient views and needs all along the clinical development path reaps a number of benefits, including time and cost savings.
This month’s news on technology, partnerships, expansions, and more includes items from IQVIA, Almac Group, Signant Health, Lonza, and other key companies.
The group has introduced a downloadable guide, interactive quiz, and other tools to inform patients from underrepresented communities about trial participation.
A leader from the trial financial management specialist suggests apps used in trials could be adjusted to better suit patients, sites and other stakeholders.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
An expert from the clinical insight specialist shares how predictive analytics could reveal info about medication adherence, disease progression, and more.
Signant Health has partnered with the software company o connect its platforms for the management of clinical supply chain inventory, labels, and content.
A leader from the behavioral science specialist shares ways to use precision engagement and other methods to increase patient adherence in clinical studies.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
The two companies are collaborating to generate subject data sets designed to help users find insights that can speed up research and improve patient care.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
